粪便
粪便细菌疗法
医学
微生物学
生物
抗生素
艰难梭菌
出处
期刊:Science
[American Association for the Advancement of Science]
日期:2021-02-04
卷期号:371 (6529): 580.5-581
标识
DOI:10.1126/science.371.6529.580-e
摘要
Clinical Trials
The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8+ T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients.
Science , this issue p. [602][1], p. [595][2]; see also p. [573][3]
[1]: /lookup/doi/10.1126/science.abb5920
[2]: /lookup/doi/10.1126/science.abf3363
[3]: /lookup/doi/10.1126/science.abg2904
科研通智能强力驱动
Strongly Powered by AbleSci AI